The lawsuit alleges that SES AI and its executives misled shareholders by overstating business prospects and the viability of deals with companies lacking significant operations. Plaintiffs claim the company artificially inflated revenue figures through service-for-purchase arrangements involving Molecular Universe and failed to disclose critical logistics constraints in late 2025 that impacted revenue timing. The company’s financial disclosures on March 4, 2026, revealed that these logistical issues delayed approximately $1.5 million in expected revenue into the first quarter of 2026. This announcement followed an investor conference in January 2026 where management failed to mention the shipment delays. Following the disclosure, SES stock dropped $0.63 per share, closing at $1.08 on March 5—a decline of nearly 37 percent. Faruqi & Faruqi partner Josh Wilson is currently investigating these claims and encourages affected shareholders to contact his office to discuss their legal options regarding the recovery of losses.